Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | POLG | P54098 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | ENO1 | P06733 | 2/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039630 | 0.85 | BTN3A1 (0.53) | BTN3A1ALDH1A1ABCB11POLA1POLG | |
| SCHEMBL2458617 | 0.81 | BTN3A1 (0.60) | BTN3A1ALDH1A1ABCB11POLA1POLG | |
| SCHEMBL9891073 | 0.79 | BTN3A1 (0.54) | BTN3A1ALDH1A1ABCB11POLA1POLG | |
| SCHEMBL27602723 | 0.79 | BTN3A1 (0.54) | BTN3A1ALDH1A1ABCB11POLA1POLG | |
| SCHEMBL9891072 | 0.79 | BTN3A1 (0.58) | BTN3A1ALDH1A1ABCB11POLA1POLG | |
| SCHEMBL4758987 | 0.79 | BTN3A1 (0.43) | BTN3A1ALDH1A1ABCB11POLA1POLG | |
| SCHEMBL17036722 | 0.77 | FAP (0.41) | BTN3A1FAP | |
| SCHEMBL10378800 | 0.77 | BTN3A1 (0.50) | BTN3A1ALDH1A1ABCB11POLA1POLG | |
| SCHEMBL29322963 | 0.76 | BTN3A1 (0.51) | BTN3A1ALDH1A1ABCB11POLA1POLG | |
| SCHEMBL13685840 | 0.76 | BTN3A1 (0.41) | BTN3A1ALDH1A1ENO1PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9732104-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | BTN3A1 4453/4885ALDH1A1 3312/4885ABCB11 1308/4885 |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, C9 | BTN3A1 3429/4885ALDH1A1 2728/4885ABCB11 4060/4885 |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, C9 | BTN3A1 3429/4885ALDH1A1 2728/4885ABCB11 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.